300639 凯普生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-3.212-14.6002.87642.60930.516
总资产报酬率 ROA (%)-2.868-12.6562.25431.46024.044
投入资产回报率 ROIC (%)-3.078-14.1322.76440.12528.793

边际利润分析
销售毛利率 (%)47.56047.67561.02969.36467.633
营业利润率 (%)-35.160-100.7593.85739.18540.171
息税前利润/营业总收入 (%)-41.572-102.0182.29137.96839.693
净利润/营业总收入 (%)-38.977-116.5326.20332.19333.106

收益指标分析
经营活动净收益/利润总额(%)51.03322.93517.449130.114103.498
价值变动净收益/利润总额(%)-2.369-1.10537.8701.0031.949
营业外收支净额/利润总额(%)3.6791.350-15.710-3.069-1.570

偿债能力分析
流动比率 (X)5.0655.0416.2553.2293.767
速动比率 (X)4.8614.8926.0593.1423.550
资产负债率 (%)12.93112.46910.95122.45417.875
带息债务/全部投入资本 (%)2.6652.0570.7292.2614.518
股东权益/带息债务 (%)3,588.9784,668.23113,367.9604,194.7152,062.472
股东权益/负债合计 (%)693.589712.904775.256324.196422.329
利息保障倍数 (X)8.202-845.860-2.198-755.637278.471

营运能力分析
应收账款周转天数 (天)542.489658.279751.262123.204113.309
存货周转天数 (天)76.90169.69391.29127.91150.649